What is the impact of Novartis's cancer treatments on patient outcomes?
Novartis's cancer treatments have had a profound impact on patient outcomes. For instance, the introduction of targeted therapies like Gleevec has transformed the prognosis for patients with chronic myeloid leukemia, turning it from a fatal disease into a manageable condition. Similarly, therapies like Kymriah offer new hope for patients with refractory or relapsed blood cancers, providing options where conventional treatments have failed.
